What is it about?
Cost of chemotherapeutic agents compared form a community generic outlet and brads available in India for the treatment of Breast Cancer. This work provides an insight in to cost sensitive Indian market for chemotherapy.
Featured Image
Photo by Allie Smith on Unsplash
Why is it important?
This work provides insights that, substituting available generic chemotherapeutic drugs can bring a potential cost savings, reducing out of pocket expenditure and can make every patient to adhere to medications without restriction of economic crisis. Thus will help healthcare professionals to take informed decisions while treating patients with Breast Cancer. It also serves as a reckoner for policy makers to take policy decisions for public spending.
Perspectives
As an individual involved in Health economics research I always believed that researchers should be able to contribute to the cause of society. These is always dearth of evidence form Indian context. This is one such opportunity for me to generate evidence for the benefit healthcare professionals to act upon. I hope this work also help policy makers to spend tax payers money wisely.
Pradeep Muragundi
Manipal College of Pharmaceutical Sciences
Read the Original
This page is a summary of: Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India, Expert Review of Pharmacoeconomics & Outcomes Research, July 2019, Taylor & Francis,
DOI: 10.1080/14737167.2019.1637735.
You can read the full text:
Contributors
The following have contributed to this page
